Compare BBNX & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBNX | MFIC |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2025 | 2004 |
| Metric | BBNX | MFIC |
|---|---|---|
| Price | $29.73 | $11.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $28.09 | $12.96 |
| AVG Volume (30 Days) | ★ 672.2K | 615.1K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 12.75% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | $88,570,000.00 | ★ $324,678,000.00 |
| Revenue This Year | $52.13 | $9.27 |
| Revenue Next Year | $36.16 | N/A |
| P/E Ratio | ★ N/A | $11.16 |
| Revenue Growth | ★ 67.01 | 11.35 |
| 52 Week Low | $8.89 | $10.18 |
| 52 Week High | $32.71 | $14.74 |
| Indicator | BBNX | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 44.58 |
| Support Level | $28.00 | $11.80 |
| Resistance Level | $30.50 | $12.02 |
| Average True Range (ATR) | 1.82 | 0.16 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 38.33 | 21.60 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.